Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448247 · ClinicalTrials.gov registry record · Phase 1
A Study of SPY001-001 in Healthy Volunteers
A Phase 1 study, sponsored by Spyre Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT06448247 is a Phase 1 study that has completed, run by Spyre Therapeutics. The registered enrollment target is 96 participants.
The verdict
NCT06448247, a Phase 1 study, has completed, sponsored by Spyre Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.
Interventions
- OTHER Placebo
- DRUG SPY001-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-06-06 |
| Est. Completion | 2026-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06448247
The ClinicalTrials.gov registry entry for NCT06448247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spyre Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06448247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06448247 about?
NCT06448247 is a clinical study titled "A Study of SPY001-001 in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.
What is the current status of trial NCT06448247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-06-06. Estimated completion is 2026-03-10.
What interventions are being tested in trial NCT06448247?
The interventions under investigation include: Placebo (OTHER), SPY001-001 (DRUG).
Who is sponsoring clinical trial NCT06448247?
This trial is sponsored by Spyre Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.